预约演示
更新于：2026-02-27
Gadobenate Dimeglumine
钆贝葡胺
更新于：2026-02-27
概要
基本信息
原研机构 |
非在研机构 |
权益机构- |
最高研发阶段批准上市 |
首次获批日期 澳大利亚 (2003-07-07), |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C29H44GdN4O16 |
InChIKeyCJORWGYBYNJSPN-BMWGJIJESA-J |
CAS号127000-20-8 |
关联
30
项与 钆贝葡胺 相关的临床试验CTRI/2023/06/054128
Active Surveillance Study of the Safety of MultiHance®in India.
NCT04910425
Phase II Study to Evaluate the Performance of PSMA-Targeted 18F-DCFPyL PET/MRI for the Detection of Clinically Significant Prostate Cancer in Men Presenting Following a Positive Screen for Prostate Cancer
NCT04973007
Evaluation of Liver MR With an Abbreviated Gadobenate Dimeglumine Hepatobiliary Phase Protocol in Comparison to Liver MR With Gadoxetate Disodium for the Detection of Hepatic Metastases
100 项与 钆贝葡胺 相关的临床结果
登录后查看更多信息
100 项与 钆贝葡胺 相关的转化医学
登录后查看更多信息
100 项与 钆贝葡胺 相关的专利（医药）
登录后查看更多信息
537
项与 钆贝葡胺 相关的文献（医药）2026-02-06AMERICAN JOURNAL OF NEURORADIOLOGY
Prospective MR Evaluation of Endolymphatic Hydrops Using Half-dose Gadopiclenol.
Article
作者: Landegger, Lukas D ; Fu, Fanrui ; Blevins, Nikolas ; Christodoulou, Rafail ; Malik, Sachin ; Fischbein, Nancy ; Pham, Nancy
BACKGROUND AND PURPOSE:
Gadopiclenol is a next-generation macrocyclic gadolinium-based contrast agent (GBCA) distinguished by its high T1 relaxivity and kinetic stability. It was developed to address the clinical need for reduced gadolinium dosing while maintaining high diagnostic accuracy, thereby minimizing potential long-term risks associated with gadolinium retention. Although various neuroradiology applications have been explored, the potential benefits of gadopiclenol's increased T1 relaxivity have not been investigated for the purpose of evaluating endolymphatic hydrops (EH) using delayed contrast-enhanced inner ear imaging.
MATERIALS AND METHODS:
We prospectively enrolled 26 consecutive patients at our institution's Otology clinic based on the 2015 American Academy of Otolaryngology-Head and Neck Surgery criteria for Ménière disease (MD), including acute or fluctuating symptoms of vertigo, hearing loss, tinnitus, or aural fullness. Each patient underwent 4-hour delayed contrast-enhanced inner ear imaging at 3T with half-dose (0.05 mmol/kg) GBCA administration using gadopiclenol. The contrast-to-noise ratio (CNR) and signal-to-noise ratio (SNR) were determined. Assessment of blood-labyrinthine barrier (BLB) permeability, utricle-saccule discrimination, and endolymphatic hydrops was performed by two head and neck neuroradiologists. Image quality, SNR, and CNR was compared to previously published data that utilized the same technical parameters with a contrast dose of 0.1 mmol/kg.
RESULTS:
Fifty-one ears were analyzed. One ear was excluded based on a prior history of left labyrinthectomy after failed medical management of MD. There were 31 symptomatic and 20 asymptomatic ears determined by clinical and hearing evaluation. Delayed contrast-enhanced inner ear imaging with gadopiclenol at 0.05 mmol/kg provided comparable CNR and SNR to gadobenate dimeglumine at 0.1 mmol/kg, with no statistically significant difference (P > 0.05). There was excellent interobserver agreement for the grading EH (κ>0.80).
CONCLUSIONS:
Our study demonstrates that 3D-FLAIR inner ear imaging using gadopiclenol at 0.05 mmol/kg is a reliable method for detecting clinically concordant EH and that image quality, based on qualitative and quantitative metrics, is comparable to a previously published study using gadobenate dimeglumine at a single-dose of 0.1 mmol/kg.
2026-01-02Expert Opinion On Drug Safety
Anaphylactic risk associated with iodinated and gadolinium-based contrast media
Article
作者: Cui, Le ; Bian, Sainan ; Guan, Kai ; Xue, Huadan ; Wang, Zixi ; Zhao, Bin ; Li, Lisha ; Xu, Yingyang
BACKGROUND:
This study aimed to analyze the risk signals of iodinated and gadolinium-based contrast media associated with anaphylaxis.
RESEARCH DESIGN AND METHODS:
Data from the United States Food and Drug Administration Adverse Event Reporting System (FAERS) were retrospectively reviewed from January 2004 to September 2022. Disproportionality and Bayesian analyses were used in data mining to screen for suspected anaphylaxis using contrast media.
RESULTS:
A total of 1240 reports of anaphylaxis associated with contrast media were identified (464 men, 37.4%). The average age of anaphylaxis associated with iodinated contrast media (ICM) and gadolinium-based contrast media (GBCM) was 56.8 ± 17.2 and 50.9 ± 18.0 years old, respectively (p < .001). Among ICM, iopamidol showed the highest reporting odds ratio (ROR) (29.0), and amidotrizoate showed the lowest ROR (7.4). Among low-osmolality ICM, iopamidol had the highest ROR (29.0), and iopromide had the lowest ROR (8.8). Among the macrocyclic agents, gadoteridol had the highest ROR (37.3), while gadoterate meglumine had the lowest (10.4). Among the linear agents, gadobenate dimeglumine had the highest ROR (28.8), and gadodiamide had the lowest (1.4). The mortality rate in ICM was significantly higher than that in GBCM (p < 0.001).
CONCLUSIONS:
This study provides clinicians and pharmacists evidence for risk signals of anaphylactic reactions among contrast agents.
2026-01-01JOURNAL OF MAGNETIC RESONANCE IMAGING
Evaluation of Living Liver Donors Using Dual‐Contrast‐Agent Magnetic Resonance Imaging (
MRI
) and Cholangiopancreatography (
MRCP
)—Technical Development
Review
作者: Parikh, Neehar D. ; Waits, Seth ; Sonnenday, Christopher ; Aslam, Anum ; Mendiratta‐Lala, Mishal ; Chahine, Reve ; Davenport, Matthew S. ; Weadock, William ; Hussain, Hero
ABSTRACT:
The indications for liver transplantation continue to expand to meet the growing need of patients with end‐stage liver disease and select hepatic malignancies. Living donor liver transplantation allows for access to transplant with recipient outcomes superior to deceased donor liver transplantation. To ensure absolute safety of the donor and optimal outcome of the recipient, potential liver donors are subjected to an exhaustive preoperative evaluation. Radiological studies play a pivotal role in assessing the donor liver anatomy to assess suitability for donation and to facilitate surgical planning. Many living donor centers supplement single‐agent contrast‐enhanced MRCP (gadobenate dimeglumine or gadoxetate disodium) with contrast‐enhanced CT angiography (CTA) for delineation of arterial anatomy. Excellent hepatic and portal venous mapping as well as biliary tract visualization has been seen, eliminating the need for CTA in studies. This review provides a case‐based analysis of the proposed dual‐contrast‐enhanced MRCP protocol, emphasizing the advantages of a single diagnostic study over traditional multi‐modality approaches while also discussing potential limitations and areas requiring further investigation.Evidence level: 4.Technical efficacy: Stage 1.
47
项与 钆贝葡胺 相关的新闻（医药）2026-02-14
2025-12-31
一致性评价
2025-12-09
100 项与 钆贝葡胺 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 动脉闭塞性疾病 | 美国 | 2012-07-06 | |
| 血管疾病 | 美国 | 2004-11-23 | |
| 中枢神经系统疾病 | 澳大利亚 | 2003-07-07 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 颈动脉疾病 | 临床3期 | 中国 | 2009-09-01 | |
| 肾脏疾病 | 临床3期 | 中国 | 2009-09-01 | |
| 外周动脉疾病 | 临床3期 | 意大利 | 2006-12-01 | |
| 血管闭塞性疾病 | 临床3期 | 意大利 | 2006-12-01 | |
| 外周动脉闭塞性疾病 | 临床3期 | 奥地利 | 2006-08-17 | |
| 中枢神经系统结核 | 临床1期 | 波兰 | 2006-09-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床2期 | 12 | 壓簾蓋壓選餘觸遞衊願(壓簾廠蓋鹹選築鹹夢顧) = 窪艱選遞構淵壓獵鏇壓 襯選窪鏇醖夢艱鏇憲齋 (網憲糧夢鹹鏇觸獵窪選, 0.83) 更多 | - | 2025-02-12 | |||
临床2期 | 30 | 糧糧遞窪鹽壓網積淵獵 = 築衊醖願膚選獵顧積觸 鹽獵鏇網憲遞糧鬱齋鑰 (醖簾鑰衊鹹衊願壓構醖, 觸夢壓築獵築網選齋簾 ~ 醖獵餘鑰鏇鹽糧遞鹹願) 更多 | - | 2017-11-07 | |||
N/A | 45 | 網遞憲艱鏇齋積鹹構壓(顧繭選積襯範網鏇網鏇) = 鬱獵鹹壓顧餘膚鬱觸鏇 衊鹽夢鏇壓窪範鏇襯選 (衊醖艱鏇製齋窪鹹廠構, 齋觸齋鬱製願選選鏇鑰 ~ 鏇膚繭齋網積鏇積鏇糧) 更多 | - | 2017-09-26 | |||
临床3期 | - | 46 | 選鹽構壓餘糧鏇齋淵簾(鬱構觸構願網獵鹹選鏇) = 積餘範積夢觸選糧鏇餘 觸鹽鏇選選醖蓋齋遞窪 (構齋獵鬱餘淵獵衊網築 ) 更多 | 积极 | 2013-04-01 | ||
選鹽構壓餘糧鏇齋淵簾(鬱構觸構願網獵鹹選鏇) = 築鬱餘鹽構窪獵網積遞 觸鹽鏇選選醖蓋齋遞窪 (構齋獵鬱餘淵獵衊網築 ) 更多 | |||||||
临床3期 | - | 壓構淵醖鹽獵簾願衊鹹(蓋膚築齋蓋鹹窪衊鬱獵) = 選獵鹹獵獵廠繭窪鑰壓 鏇製範遞壓餘遞獵獵鹹 (鏇淵餘製製衊選鏇網簾 ) 更多 | 积极 | 2011-02-01 | |||
壓構淵醖鹽獵簾願衊鹹(蓋膚築齋蓋鹹窪衊鬱獵) = 構壓衊醖鑰鹹築製夢鹽 鏇製範遞壓餘遞獵獵鹹 (鏇淵餘製製衊選鏇網簾 ) 更多 | |||||||
临床3期 | 92 | 鬱醖淵膚觸獵淵廠範網(選鑰廠構鑰積壓積網衊) = 夢膚淵廠觸鑰艱遞醖衊 衊壓襯襯憲構鹹獵夢衊 (夢積範繭鏇鏇醖構築衊, 1.16) 更多 | - | 2010-10-06 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
生物医药百科问答
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用